The field of ImmunoOncology has opened up new possibilities in cancer therapy.
Depending on the indication and the selected therapy, different biomarkers are available. One of the most prominent biomarkers is the expression level of PD-L1, which is determined by Immunohistochemistry. medac offers two excellent clones for PD-L1. First the well-known clone 28-8 which is subject of numerous scientific studies and secondly the clone ZR3. The clone ZR3 is a cost-effective alternative and has already been tested in different ring trials (NordicQC, QuiP).
Furthermore also the interaction between tumor and surrounding tissue plays an essential role. In particular, the predictive and prognostic significance of tumor infiltrating lymphocytes (TILs) is subject of current research. medac offers a wide range of markers for the immune system, such as CD3, CD4, CD8 or FoxP3. In addition, medac also offers exciting markers, like CTLA-4, PD-1 and LAG-3 which are known to have immunomodulatory functions.

• Homepage Brochure Immunooncological Markers